COVID-19 and QT interval prolongation: more than just drug toxicity?

Europace. 2020 Oct 1;22(10):1479. doi: 10.1093/europace/euaa145.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adrenergic beta-Agonists / administration & dosage
  • Aged
  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / adverse effects
  • Azithromycin* / administration & dosage
  • Azithromycin* / adverse effects
  • Betacoronavirus / isolation & purification
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques
  • Coronavirus Infections* / blood
  • Coronavirus Infections* / diagnosis
  • Coronavirus Infections* / physiopathology
  • Coronavirus Infections* / therapy
  • Electrocardiography / methods
  • Humans
  • Hydroxychloroquine* / administration & dosage
  • Hydroxychloroquine* / adverse effects
  • Isoproterenol / administration & dosage
  • Long QT Syndrome* / blood
  • Long QT Syndrome* / diagnosis
  • Long QT Syndrome* / drug therapy
  • Long QT Syndrome* / etiology
  • Male
  • Myocarditis* / blood
  • Myocarditis* / complications
  • Myocarditis* / virology
  • Pandemics*
  • Pneumonia, Viral* / blood
  • Pneumonia, Viral* / diagnosis
  • Pneumonia, Viral* / etiology
  • Pneumonia, Viral* / physiopathology
  • Pneumonia, Viral* / therapy
  • SARS-CoV-2
  • Treatment Outcome
  • Troponin I / blood*

Substances

  • Adrenergic beta-Agonists
  • Anti-Infective Agents
  • Troponin I
  • Hydroxychloroquine
  • Azithromycin
  • Isoproterenol